WORCESTER, Mass. and TORONTO, April 4, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) announced today the publication of a report comparing the clinical characteristics of three different immunotherapeutic peptide vaccines designed for immunotherapy of breast cancer. One of those, AE37, is being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com).
The AE37 peptide, which is modified by proprietary technology to increase specific immunity against the HER2 protein expressed on cancer cells, is currently the subject of a randomized and controlled Phase II trial in patients with breast cancer as well as a Phase I trial in patients with prostate cancer that was recently completed.
The report, entitled "Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines", appeared in the February issue of Expert Review of Vaccines. The three peptides compared were AE37, E75 (also known as NeuVax™) and GP2. Both E75 and GP2 represent unmodified peptides derived from the HER2 protein selected to stimulate cytotoxic CD8+ T cells.
In contrast, AE37 is a modified HER2-derived peptide designed to stimulate CD4+ T helper cells (in addition to CD8+ T cells). All peptides were shown to be safe and well tolerated by breast cancer patients. The order of potency of specific HER2 immunity induced by the peptides was: AE37 followed by GP2 followed by E75. Though not yet confirmed, there is evidence suggesting that a better immunological response against HER2 is associated with decreased disease recurrence and mortality.
A further study is being presented at the 102nd Annual Meeting of the American Assoc
|SOURCE Generex Biotechnology Corporation|
Copyright©2010 PR Newswire.
All rights reserved